Canopy Growth Corporation reported its financial results for the second quarter of fiscal year 2025, revealing a net revenue of $63 million. The company experienced a significant operating loss of $46 million from continuing operations, a sharp decline compared to a loss of $7 million in the same quarter of the previous year. The decline in revenue was attributed to a 9% decrease overall, despite strong performance in its Storz & Bickel product line, which saw a 32% revenue increase. Additionally, medical cannabis revenue grew by 16% in Canada and 12% internationally. The prior year's results had benefitted from the sale of a facility in Smiths Falls, Ontario. Looking ahead, Canopy Growth expressed optimism for the second half of fiscal 2025, anticipating continued strength in its medical cannabis business and improved performance in the adult-use sector, bolstered by restored supply from Wana and expanded distribution efforts.